Status:
UNKNOWN
Expression Analysis of Urinary Exosome in Type 2 Diabetic Nephropathy and Evaluation of Its Clinical Diagnostic Value
Lead Sponsor:
Yipeng Liu
Conditions:
Diabetic Nephropathy
Eligibility:
All Genders
18-90 years
Brief Summary
Expression analysis of urinary exosome miR-142-3p in type 2 diabetic nephropathy and evaluation of its clinical diagnostic value
Detailed Description
1. Preliminary screening of miRNAs: Through GEO database and reading related literature, miRNAs differentially expressed in type 2 diabetes and diabetic nephropathy were selected as potential candidat...
Eligibility Criteria
Inclusion
- Age ≥18 years old;
- Previously diagnosed with type 2 diabetes;
- Typical diabetic symptoms (polydipsia, polydipsia, polyuria and weight loss) plus random blood glucose ≥11.1mmol/l;
- Fasting blood glucose ≥7.0mmol/l, fasting is defined as at least 8 hours without intake of calories;
- Oral glucose tolerance test (OGTT) 2-hour blood glucose ≥11.1mmol/l, using a glucose load equivalent to 75 grams of anhydrous glucose dissolved in water (venous blood was drawn in all patients;
- With or without UACR≥30mg/g.
Exclusion
- (1) Refused to enroll patients; （2）Type 1 diabetic nephropathy and other special types of diabetic nephropathy; （3）Patients with kidney stones and urinary system infection; （4）Patients with autoimmune system diseases, malignant tumors, and blood system diseases; （5）Patients with severe chronic cardiopulmonary disease, chronic liver and kidney disease; （6）Patients with severe infectious diseases; （7）Use of glucocorticoids, immunosuppressants or cytotoxic drugs.
Key Trial Info
Start Date :
June 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2024
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT06097351
Start Date
June 1 2020
End Date
January 31 2024
Last Update
October 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qianfoshan Hospital
Jinan, Shandong, China, 250000